Ku80蛋白在前列腺癌中表达的临床研究

目的 探讨Ku80蛋白表达与前列腺癌血清PSA和前列腺癌Gleason分级之间的关系.方法 采用HE染色观察前列腺癌组织学形态并进行分级,免疫组化SP法检测前列腺癌组织中Ku80蛋白表达,按前列腺癌Gleason评分和血清PSA值分组,比较各组间Ku80蛋白表达水平.结果 58例前列腺癌标本中Ku80蛋白均呈阳性表达,伴随着前列腺癌Gleason评分和血清PSA值升高,Ku80蛋白表达强度明显增强.结论 Ku80蛋白表达水平能预测前列腺癌预后及治疗效果,可用于临床指导个体化治疗.     

前列腺增生,不典型增生及前列腺癌的定量图像研究

采用电子计算机图像分析仪选择１５项几何参数作为前列腺良性增生、前列腺不典型增生、前列腺癌的定量诊断指标。测定数据输入计算机进行统计学处理。结果得出多项参数在各组间均有显著性差异，并优选出其中５项参数ＮＰ、ＮＡＶ、ＮＲ、ＣＰ、Ｖ－Ｎ／Ｃ作为建立前列腺癌专家诊断系统的科学数据。     

Ku70蛋白在前列腺癌中表达的临床研究

目的 探讨Ku70蛋白表达与前列腺癌Gleason评分及前列腺特异抗原(prostate specific antigen,PSA)的关系.方法 采用HE染色观察组织学形态,免疫组化SP法检测前列腺癌组织中Ku70蛋白表达,按前列腺癌Gleason评分和血清PSA值分组,比较各组间Ku70蛋白表达水平.结果 58例前列腺癌标本中Ku70蛋白均呈阳性表达,其表达强度与前列腺癌Gleason评分和血清PSA呈明显负相关.结论 Ku70蛋白表达水平能帮助判断前列腺癌预后及评价治疗效果,可用于临床指导个体化治疗.     

上海市238例前列腺癌新发病例的临床调查

为了解前列腺癌临床流行病学情况，对上海市市区前列腺癌新发病例进行全人群对照研究。２３８例前列腺癌年龄构成为：５０岁～１１例（４．６％），６０岁～６４例（２６．９％），７０岁～１１５例（４８．３％），８０岁～４５例（１８．９％），９０～９３岁３例（１．３％）。肛指检查阳性率６５．５％，合并良性前列腺增生症占５６．３％。临床分期Ｔ１１２例（５．４％），Ｔ２８８例（３９．８％），Ｔ３８４例（３８．０％），Ｔ４３７例（１６．８％）。９０例（３７．８％）确定有远处转移。２２０例（９２．４％）细胞类型为腺癌。１８４例患者病理分级１级２３例（１２．５％），２级７３例（３９．７％），３级８８例（４７．８％）。临床分期与肿瘤远处转移率有关（Ｐ＜０．００１）。平均血清ＰＳＡ为８７．３μｇ／Ｌ，与人群对照组及ＢＰＨ对照组有显著性差异（Ｐ＜０．００１）。对血清ＰＳＡ的价值，前列腺癌的治疗方法进行了初步探讨。     

Clinical study of incidental prostatic carcinoma

At the Center for Adult Diseases, Osaka, between 1961 and 1987, 28 cases (1.8%) of incidental prostatic adenocarcinoma were detected by transurethral or subcapsular prostatectomy for clinically benign prostatic hypertrophy (1388 cases) and cysto-prostatectomy for urinary bladder carcinoma (156). Nine (32%) and 19 (68%) cases were in stages A1 and A2, respectively. Of the 19 A2 cases, 9 were well, 9 were moderately and 1 was poorly differentiated adenocarcinoma. Five of the A2 and 1 of the A1 progressed into clinical carcinoma, but none of these patients died of the cancer. Four of these 5 A2 patients had received no treatment postoperatively and one received castration. The intervals from diagnosis to progression ranged from 11 to 78 months. The survival rates at 5 and 10 years with A1 were 75% and 75%, and those with A2 were 80% and 37%. We conclude that the patients in stage A2 should be treated because stage A2 tumors, especially those with no treatment, progress at a higher frequency than stage A1 tumors.     

前列腺偶发癌38临床分析

目的探讨前列腺偶发癌的临床分期、治疗方法选择与预后的相关性。方法回顾性分析2001—2007年良性前列腺增生术后发现的前列腺偶发癌患者38例,根据临床分期结果采用等待观察、手术去势、药物内分泌治疗及前列腺癌根治术等不同方式处理,并观察比较不同分期及相应治疗方法与预后的相关性。结果1240例良性前列腺增生手术患者中,术后检出前列腺癌38例(3.06%),T1a期16例,T1b期22例。随访6月—6年,存活率89.5%。T1a期等待观察组存活率90%,进展率10.0%;双侧睾丸切除术组存活率100%,进展率16.7%;T1a期总存活率93.8%,进展率12.5%。T1b期未行根治术组存活率81.3%,进展率37.5%;根治术组存活率为100%。与未行根治性术的T1b期相比,T1a期的总存活率高于T1b期,而进展率低于T1b期,但差异无统计学意义(P>0.05)。结论本组偶发癌检出率与报道相近。T1a期接受治疗组与等待观察组生存率相近;T1b期行双侧睾丸切除术加内分泌治疗者生存率仍低于T1a期,而进展率高于T1a期。T1b期行根治术的患者生存率高于未做根治术者。T1a期可等待观察,T1b期需积极治疗,对T1b期患者,根治性前列腺切除术可获得较好疗效。     

A histochemical study of glycosidases in benign prostatic hyperplasia and in prostatic carcinoma in the human

Summary In benign hyperplasia marked -glucuronidase and N-acetyl--glucosaminidase activity was seen in the prostatic epithelium whereas the reactions for 5 other glycosidases were only slight or negative. The intensity of the reaction for the glycosidases in prostatic carcinoma was dependent upon the degree of the differentiation. The possible importance of glycosidases for the invasiveness of prostatic carcinoma is briefly discussed.     

A clinical study of renal cell carcinoma

Eighty two cases of renal cell carcinoma, treated at our Department between July, 1971 and May, 1984, are reviewed. The highest incidence of this disease was seen in the 5th decade and the average age of the patients was 58.8 years. Male patients predominated over the female patients, the ratio being 1.6: 1. According to Robson's classification, thirty eight cases were in stage I, five cases in stage II, nine cases in stage III and thirty cases in stage IV. The overall survival rate at one, three and five years was 77, 58 and 48%, respectively. The most common symptom was macroscopic hematuria, followed by asymptomatic, lumbago and palpable mass. The site of distant metastases was most frequently in the lung, followed by the bone, liver and lymph node. There were no remarkable differences in the prognosis of stage I patients, between the group treated with preoperative renal arterial embolization and non-treated group. No remarkable difference was seen between the survival rate of the stage IV patients treated by nephrectomy and these not treated by nephrectomy. Renal arterial embolization was an effective therapeutic measure for patients with non-resectable stage IV renal cell carcinoma (p = 0.0647, compared with non-treated group).     

前列腺癌放射免疫治疗的实验研究

为评价放射免疫治疗对前列腺癌治疗效果的作用，用１３１Ｉ标记人精浆蛋白（γＳｍ）单克隆抗体对前列腺癌荷瘤裸鼠模型放射免疫治疗。３５只荷瘤裸鼠分对照组、腹腔给药组、瘤内给药组、分次给药组及非特异抗体组５组。比较各组移植物的体积，生长抑制率及动物生存时间。结果：１３１ＩγＳｍ对人前列腺癌裸鼠移植物有较强的抑制作用，在同样剂量下瘤内给药抑制效果优于其它方法给药，肿瘤生长抑制率为８５．７％。结论：１３１ＩγＳｍ放射免疫治疗可作为前列腺癌治疗的新方法     

非那雄胺间歇给药维持良性前列腺增生疗效的临床研究

目的验证非那雄胺间歇给药维持良性前列腺增生（BPH）疗效的可行性并观察间歇给药是否能够减少勃起功能障碍、性欲减退等性功能相关不良反应的发生率。方珐收集泌尿外科门诊符合入组条件的60例患者,将受试者均分为3组,分别予非那雄胺（保列治）5mg1次／d、1次／2d及1次／3d口服,进行为其6个月的随访。以国际前列腺症状评分（IPSS）、生活质量评分（QOL）、前列腺特异性抗原（PSA）、最大尿流率（Qmax）及超声测量作为治疗有效性参数,以勃起功能障碍国际问卷5（IIEF-5）作为治疗前后性功能评价参数。结果1次／3d给药组多数患者于试验开始后2～3周出现明显症状加重,提前终止该组实验。随访1次／d及1次／2d给药组6个月,1次／2d给药组勃起功能障碍发生率略低于1次／d给药组。结论非那雄胺隔日间歇给药可能能够达到维持BPH疗效、减少药物副反应的目的,但这一推断尚需通过更大规模的随机、双盲多中心试验进行证实。     

Histological grading of prostatic carcinoma and its clinical evaluation.

The clinical control of patients with T1--T3, N0--M0 prostatic carcinomas allows us to draw the following conclusions regarding the grading. (1) The grading of the primary tumor is of great help in establishing the prognosis. (2) The results of the various applied treatments, like radical prostatectomy, radiation, and heterosexual hormone therapy, depend on the primary grade. The use of cytostatics in badly or undifferentiated prostatic carcinomas deserves on the contrary, better attention. (3) The changing of the grading at the various check-ups is of great therapeutical significance.     

A clinical study on renal cell carcinoma

One hundred and thirty-two patients with renal cell carcinoma, treated by the TEKK Group, during the period from 1962 to 1983 were clinically reviewed. The patients ranged in age from 13 to 77 years with a mean age of 57.3 years, and were 89 men and 44 women, with a sex ratio of 2.07 to 1. The most common symptom was hematuria (55.4%), followed by palpable mass (19.2%), pain (13.8%) and fever (6.9%). The distant metastasis was observed in 26 patients (19.7%), mostly in the lung (54%) and the bone (19%). Overall estimated survival rates at 1,3 and 5 year were 83.0%, 58.2% and 56.9% respectively. The prognosis of the patients with renal cell carcinoma was dependent upon affected site, age, ESR, CRP, alpha 2-globulin and distant metastasis.     

A case of prostatic small cell carcinoma

A 66-year-old man was referred to our hospital with a complaint of lumbago. Digital rectal examination showed an enlarged, irregular prostate with stony hardness. The serum level of prostate specific antigen (PSA) was elevated. Abdominal computed tomography showed enlarged common iliac and paraaortic lymph nodes, and multiple liver metastases. Bone scintigraphy showed multiple bone metastases. Histological and immunohistochemical examinations indicated small cell carcinoma and adenocarcinoma of the prostate. Chemotherapy could not be performed due to acute hepatic failure. The patient died 1 month after his first visit.